TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in
Multiple Sclerosis
Presented at the 2022 European Committee for Treatment and Research in
Multiple Sclerosis

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of
multiple sclerosis (RMS)
, presented at the 2022 European Committee for Treatment and Research in
Multiple Sclerosis
(ECTRIMS) annual meeting. Links to each of the presentations are included below. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to share additional exploratory analyses from the ULTIMATE I & II Phase 3 trials at the ECTRIMS conference this week. We believe the data continue to show an encouraging pro ublituximab to treat patients with RMS, if approved, and look forward to our upcoming PDUFA goal date of December 28, 2022.” PRESENTATIONS: Poster Presentation:Disability Changes in the Absence of Relapse in the Phase 3 ULTIMATE I and II Studies of ublituximab Versus teriflunomide in Participants With Relapsing Multiple Sclerosis Lead Author: Sibyl Wray, MD Hope Neurology, Knoxville, TN Poster Presentation:Functional systems scores and expanded disability status scale score evaluations in the ULTIMATE I and II studies of ublituximab versus teriflunomide in participants with relapsing multiple sclerosis Lead Author: Bruce A. C. Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA Poster Presentation:Ublituximab treatment is associated with a significant proportion of patients achieving NEDA-4 Lead Author: Enrique Alvarez, MD, University of Colorado, Aurora, CO Poster Presentation:Disease Outcomes With ublituximab in Treatment-Naive Participants: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis Lead Author: Lawrence Steinman, MD Stanford University, Stanford, CA, USA Poster Presentation:B-Cell Depletion and Return in Participant Subgroups of the Phase 3 ULTIMATE I and II Studies of ublituximab Versus teriflunomide in Participants With Relapsing Multiple Sclerosis Lead Author: Edward J. Fox, MD, PhD, Central Texas Neurology Consultants, Round Rock, TX The above presentations are also available on the Publications page, located within the Pipeline section, of the Company’s website at ABOUT THE ULTIMATE I & II PHASE 3 TRIALS ULTIMATE I and ULTIMATE II are two independent Phase 3, randomized, double-blinded, active-controlled, global, multi-center studies evaluating the efficacy and safety/tolerability of ublituximab (450mg dose administered by one-hour intravenous infusion every 6 months, following a Day 1 infusion of 150mg over four hours and a Day 15 infusion of 450mg over one hour) versus teriflunomide (14mg oral tablets taken once daily) in subjects with relapsing forms of
Multiple Sclerosis (RMS)
. The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries. These trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University and were conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). As previously announced, both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) compared to teriflunomide over a 96-week period (p<0.005 in each trial). Additional information on these clinical trials can be found at (NCT03277261; NCT03277248). ABOUT UBLITUXIMAB Ublituximab is an investigational glycoengineered monoclonal antibody that targets a unique epitope on
B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions, including antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC), leading to destruction of the cell. Additionally, ublituximab is uniquely designed, to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, has been shown to enhance the potency of ublituximab, especially the ADCC activity. Targeting
using monoclonal antibodies has proven to be an important therapeutic approach for the management of
B-cell malignancies
autoimmune disorders
, both diseases driven by the abnormal growth or function of B-cells. ABOUT
Relapsing multiple sclerosis (RMS)
is a
chronic demyelinating disease
of the central nervous system (CNS) and includes people with
relapsing-remitting multiple sclerosis (RRMS)
and people with
secondary progressive multiple sclerosis (SPMS)
who continue to experience relapses. RRMS is the most common form of
multiple sclerosis (MS)
and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with
in the United States and approximately 85% are initially diagnosed with RRMS.1,2 The majority of people who are diagnosed with RRMS will eventually transition to SPMS, in which they experience steadily worsening disability over time. Worldwide, more than 2.3 million people have a diagnosis of
ABOUT TG THERAPEUTICS TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for
B-cell diseases
. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on
B-cells, to treat patients with relapsing forms of
multiple sclerosis (RMS)
. For more information, visit , and follow us on Twitter @TGTherapeutics and Linkedin. Cautionary Statement This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include but are not limited to statements regarding the results of the ULTIMATE I & II Phase 3 studies and ublituximab as a potential treatment for relapsing forms of
Multiple Sclerosis (RMS)
. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the following: the risk that the data from the ULTIMATE I & II trials that we announce or publish may change, or the perceived product pro be impacted, as more data or additional endpoints are analyzed; the risk that data may emerge from future clinical studies or from adverse event reporting that may affect the perceived safety and tolerability pro commercial potential of ublituximab; the risk that the clinical results from the ULTIMATE I & II trials will not support regulatory approval of ublituximab to treat RMS for efficacy, safety or other issues or, if approved, that we will not receive regulatory approval within the timeline projected; the risk that if approved, ublituximab will not be commercially successful; our ability to expand our commercial infrastructure, and successfully launch, market and sell ublituximab in RMS if approved; the Company’s reliance on third parties for manufacturing, distribution and supply, and a range of other support functions for our commercial and clinical products, including ublituximab; the uncertainties inherent in research and development; and the risk that the ongoing COVID-19 pandemic and associated government control measures have an adverse impact on our research and development plans or commercialization efforts. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in our other filings with the SEC. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only CONTACT: Investor Relations Email: Telephone: 1.877.575.TGTX (8489), Option 4 Media Relations: Email: Telephone: 1.877.575.TGTX (8489), Option 6 ____________________________________________________ 1.
Prevalence. National Multiple Sclerosis Society website. . Accessed October 26, 2020. 2.
Multiple Sclerosis
International Federation, 2013 via Datamonitor p. 236.